CA3040423A1 - Anti-edb antibodies and antibody-drug conjugates - Google Patents

Anti-edb antibodies and antibody-drug conjugates Download PDF

Info

Publication number
CA3040423A1
CA3040423A1 CA3040423A CA3040423A CA3040423A1 CA 3040423 A1 CA3040423 A1 CA 3040423A1 CA 3040423 A CA3040423 A CA 3040423A CA 3040423 A CA3040423 A CA 3040423A CA 3040423 A1 CA3040423 A1 CA 3040423A1
Authority
CA
Canada
Prior art keywords
antibody
edb
seq
cancer
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3040423A
Other languages
English (en)
French (fr)
Inventor
Andrea Therese HOOPER
Kimberly Ann Marquette
Chakrapani Subramanyam
Hans-Peter Gerber
Chad Michael May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CA3040423A1 publication Critical patent/CA3040423A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3040423A 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates Pending CA3040423A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409081P 2016-10-17 2016-10-17
US62/409,081 2016-10-17
PCT/IB2017/056093 WO2018073680A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Publications (1)

Publication Number Publication Date
CA3040423A1 true CA3040423A1 (en) 2018-04-26

Family

ID=60117722

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3040423A Pending CA3040423A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Country Status (22)

Country Link
US (5) US20190269791A1 (enExample)
EP (3) EP4617283A2 (enExample)
JP (4) JP7039577B2 (enExample)
KR (1) KR102338660B1 (enExample)
CN (2) CN116251196A (enExample)
AU (3) AU2017344440B2 (enExample)
CA (1) CA3040423A1 (enExample)
DK (1) DK3525828T3 (enExample)
ES (1) ES3007557T3 (enExample)
FI (1) FI3525828T3 (enExample)
HR (1) HRP20250056T1 (enExample)
HU (1) HUE070615T2 (enExample)
IL (2) IL266112B2 (enExample)
LT (1) LT3525828T (enExample)
MX (2) MX2019004434A (enExample)
PL (1) PL3525828T3 (enExample)
PT (1) PT3525828T (enExample)
RS (1) RS66524B1 (enExample)
RU (1) RU2758632C2 (enExample)
SG (1) SG11201903400WA (enExample)
SI (1) SI3525828T1 (enExample)
WO (1) WO2018073680A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2020123425A2 (en) * 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
CN119546327A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
WO2025011561A1 (en) * 2023-07-10 2025-01-16 Wuxi Xdc (Shanghai) Co., Ltd. Antibody-drug conjugates and production thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
ATE526039T1 (de) * 2000-02-24 2011-10-15 Philogen Spa Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
CA2400622A1 (en) 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US7498029B2 (en) 2001-05-01 2009-03-03 The General Hospital Corporation Photoimmunotherapies for cancer using combination therapies
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
RU2352582C2 (ru) * 2002-01-03 2009-04-20 Шеринг Акциенгезельшафт Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей
AU2003219370B2 (en) 2002-03-11 2009-01-15 Philogen S.P.A Antibodies derived rom anti ED-B L19 and targeting tumor vasculature
WO2004012735A2 (en) * 2002-07-31 2004-02-12 Schering Ag New effector conjugates, process for their production and their pharmaceutical use
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
ES2341126T3 (es) * 2005-05-11 2010-06-15 Philogen S.P.A. Proteina de fusion del anticuerpo l19 contra fibronectina ed-b e interleucina 12.
NZ567202A (en) 2005-10-05 2012-02-24 Commw Scient Ind Res Org Silk proteins from Hyhemonptera species containing heptad repeats that form coiled coil tertiary structures
EP1842553A1 (en) * 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
JP2009535372A (ja) * 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
TWI412367B (zh) * 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
EP2653478B1 (en) 2007-04-02 2016-10-05 Philogen S.p.A. A novel antigen associated with the neovasculature of tumour metastases
KR101781638B1 (ko) 2007-07-25 2017-09-25 필로겐 에스.피.에이. 종양 전이의 신생혈관과 관련된 피브리노겐의 ｅｄ-ａ 항원
ES2382058T3 (es) * 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
ES2738700T3 (es) * 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
MX2012002014A (es) 2009-08-17 2012-06-13 Roche Glycart Ag Inmunoconjugados dirigidos.
EP2621535A1 (en) 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
BR112015018899B1 (pt) * 2013-02-08 2023-09-26 Novartis Ag Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
WO2014174105A1 (en) * 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
KR101871088B1 (ko) * 2014-01-27 2018-06-25 화이자 인코포레이티드 이관능성 세포독성제
GB2538023A (en) * 2014-02-03 2016-11-02 Philochem Ag Targeted drug conjugates
US11602525B2 (en) * 2014-04-25 2023-03-14 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
TWI703160B (zh) 2015-11-30 2020-09-01 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
TWI726942B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體

Also Published As

Publication number Publication date
US20230241235A1 (en) 2023-08-03
IL266112B2 (en) 2024-07-01
US11833216B2 (en) 2023-12-05
HUE070615T2 (hu) 2025-06-28
JP2025175010A (ja) 2025-11-28
MX2024003463A (es) 2024-04-03
JP2022016581A (ja) 2022-01-21
SG11201903400WA (en) 2019-05-30
JP7383682B2 (ja) 2023-11-20
IL266112B1 (en) 2024-03-01
SI3525828T1 (sl) 2025-04-30
IL310865A (en) 2024-04-01
RU2758632C2 (ru) 2021-11-01
FI3525828T3 (fi) 2025-01-27
US20240156977A1 (en) 2024-05-16
CN110087691A (zh) 2019-08-02
EP4617283A2 (en) 2025-09-17
AU2017344440A1 (en) 2019-05-02
US20240261423A1 (en) 2024-08-08
PT3525828T (pt) 2025-01-29
CN116251196A (zh) 2023-06-13
ES3007557T3 (en) 2025-03-20
EP3525828A1 (en) 2019-08-21
AU2017344440B2 (en) 2020-07-30
US20190269791A1 (en) 2019-09-05
KR102338660B1 (ko) 2021-12-10
AU2020260375B2 (en) 2023-11-30
LT3525828T (lt) 2025-02-25
EP3525828B1 (en) 2024-12-25
MX2019004434A (es) 2019-09-26
DK3525828T3 (da) 2025-02-17
RU2019111303A (ru) 2020-11-17
KR20190069493A (ko) 2019-06-19
CN110087691B (zh) 2023-02-03
WO2018073680A1 (en) 2018-04-26
US20240181071A1 (en) 2024-06-06
AU2020260375A1 (en) 2020-11-19
JP2023184697A (ja) 2023-12-28
JP2019534706A (ja) 2019-12-05
JP7039577B2 (ja) 2022-03-22
EP4635516A2 (en) 2025-10-22
PL3525828T3 (pl) 2025-03-31
RS66524B1 (sr) 2025-03-31
BR112019007760A2 (pt) 2019-09-03
RU2019111303A3 (enExample) 2020-11-17
IL266112A (en) 2019-06-30
HRP20250056T1 (hr) 2025-04-11
AU2024201216A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
US11833216B2 (en) Anti-EDB antibodies and antibody-drug conjugates
JP6629837B2 (ja) 抗ｐｔｋ７抗体−薬物コンジュゲート
US12371507B2 (en) CDCP1 antibodies and antibody drug conjugates
WO2025208105A1 (en) Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders
HK40092426A (zh) 抗-edb抗体和抗体-药物缀合物
WO2024240162A1 (en) Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
HK40012788B (en) Anti-edb antibodies and antibody-drug conjugates
HK40012788A (en) Anti-edb antibodies and antibody-drug conjugates
BR112019007760B1 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica, ácido nucleico, vetor, processo para a produção do conjugado de anticorpofármaco e uso do conjugado de anticorpo-fármaco
BR122024006481A2 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica e seus usos, processo para a produção de um conjugado de anticorpo-fármaco, anticorpo, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo e método para detectar domínio b extra de fibronectina

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190412

EEER Examination request

Effective date: 20190412

EEER Examination request

Effective date: 20190412

EEER Examination request

Effective date: 20190412

EEER Examination request

Effective date: 20190412

EEER Examination request

Effective date: 20190412

EEER Examination request

Effective date: 20190412

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240813

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240911

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240911

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250109

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250401

P12 Request for amendment of application rejected

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED NOT COMPLIANT

Effective date: 20250401